Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1

מצבים רפואיים

Metastatic Malignant Solid Neoplasm · Unresectable Malignant Solid Neoplasm

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • City of Hope Comprehensive Cancer Center, Duarte, California, United States

    Contact: Study coordinator (Site Public Contact) · becomingapatient@coh.org · 800-826-4673
    Contact: Principal Investigator (Sharonlin Bhardwaj)
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

  • UC San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Site Public Contact) · cancercto@ucsd.edu · 858-822-5354
    Contact: Principal Investigator (Shumei Kato)
  • Los Angeles General Medical Center, Los Angeles, California, United States

    Contact: Study coordinator (Site Public Contact) · uscnorrisinfo@med.usc.edu · 323-865-0451
    Contact: Principal Investigator (Varsha Tulpule)
  • USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

    Contact: Study coordinator (Site Public Contact) · 323-865-0451
    Contact: Principal Investigator (Varsha Tulpule)
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

  • UC San Diego Medical Center - Hillcrest, San Diego, California, United States

    Contact: Study coordinator (Site Public Contact) · rhabbaba@health.ucsd.edu
    Contact: Principal Investigator (Shumei Kato)
  • University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222
    Contact: Principal Investigator (Gini F. Fleming)
  • National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

    Contact: Study coordinator (Site Public Contact) · 800-411-1222
    Contact: Principal Investigator (A P. Chen)
  • National Institutes of Health Clinical Center, Bethesda, Maryland, United States

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Site Public Contact) · 617-667-9925
    Contact: Principal Investigator (Gerburg M. Wulf)
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Site Public Contact) · 877-442-3324
    Contact: Principal Investigator (Geoffrey I. Shapiro)
  • NYU Langone Hospital - Long Island, Mineola, New York, United States

    Contact: Study coordinator (Site Public Contact) · cancertrials@nyulangone.org · 212-263-4432
    Contact: Principal Investigator (Nancy Chan)
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

    Contact: Study coordinator (Site Public Contact) · CancerTrials@nyulangone.org
    Contact: Principal Investigator (Nancy Chan)
  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
    Contact: Principal Investigator (John L. Hays)
  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Site Public Contact) · ou-clinical-trials@ouhsc.edu · 405-271-8777
    Contact: Principal Investigator (Debra L. Richardson)
  • Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

    Contact: Study coordinator (Site Public Contact) · cancerinfo@hci.utah.edu · 888-424-2100
    Contact: Principal Investigator (Vaia Florou)
  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Site Public Contact) · 800-804-8824
    Contact: Principal Investigator (Michael Schweizer)
  • University of Washington Medical Center - Montlake, Seattle, Washington, United States

    Contact: Study coordinator (Site Public Contact) · 800-804-8824
    Contact: Principal Investigator (Michael Schweizer)
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
    Contact: Principal Investigator (Jeremy Kratz)
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
    Contact: Principal Investigator (Jeremy Kratz)
  • University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

מובילי המחקר
  • Geoffrey I Shapiro

    Principal Investigator

    Dana-Farber - Harvard Cancer Center LAO